The theranostic approach in oncology holds significant importance in personalized medicine and stands as an exciting field of molecular medicine. Significant achievements have been made in this field in recent decades, particularly in treating neuroendocrine tumors using 177-Lu-radiolabeled somatostatin analogs and, more recently, in addressing prostate cancer through prostate-specific-membrane-antigen targeted radionuclide therapy. The promising clinical results obtained in these indications paved the way for the further development of this approach. With the continuous discovery of new molecular players in tumorigenesis, the development of novel radiopharmaceuticals, and the potential combination of theranostics agents with immunotherapy, nuclear medicine is poised for significant advancements. The strategy of theranostics in oncology can be categorized into (1) repurposing nuclear medicine agents for other indications, (2) improving existing radiopharmaceuticals, and (3) developing new theranostics agents for tumor-specific antigens. In this review, we provide an overview of theranostic development and shed light on its potential integration into combined treatment strategies.
肿瘤学中的诊疗一体化方法在个体化医疗中具有重要意义，并已成为分子医学中一个令人振奋的领域。近几十年来，该领域已取得显著成就，特别是在使用¹⁷⁷Lu标记的生长抑素类似物治疗神经内分泌肿瘤方面，以及近期通过靶向前列腺特异性膜抗原的放射性核素疗法治疗前列腺癌方面。这些适应症中取得的良好临床结果为该方法的进一步发展铺平了道路。随着肿瘤发生发展中新分子靶点的不断发现、新型放射性药物的研发，以及诊疗一体化药物与免疫疗法潜在的联合应用，核医学正迎来重大发展机遇。肿瘤诊疗一体化策略可分为三类：(1) 将现有核医学药物拓展应用于其他适应症，(2) 改进现有放射性药物，(3) 针对肿瘤特异性抗原开发新型诊疗一体化药物。本文综述了诊疗一体化的发展现状，并探讨了其融入联合治疗策略的潜在前景。
Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future
肿瘤(癌症)患者之家